Lincoln Pharma Gets Indian Patent For Diclofenac Rectal Spray
On Tuesday, Lincoln Pharmaceuticals said it has received an Indian patent for its diclofenac rectal spray. This is a spray that is used for alleviating pain from various causes.
The patent has been awarded to Lincoln Pharmaceuticals by the Government of India for “a novel liquid rectal spray dosage form containing diclofenac & its pharmaceutically active salts” valid for twenty years, the Ahmedabad-based firm said in a regulatory filing.
The Lincoln Pharmaceuticals further said it has necessary approvals from the Drug Controller General of India (DCGI) and is planning to launch the spray in the Indian market by January 2020.
Lincoln Pharma is also planning to apply for a global patent for this novel spray solution, the filing added.
Lincoln Pharmaceuticals said its liquid rectal spray dosage offers faster & better absorption of the drug resulting in quick relief and speedy recovery to patients compared to the existing therapeutic options available.
The clinical trials conducted suggest that Lincoln pharma’s diclofenac rectal spray is highly effective in patients suffering from pre & postoperative pain, gynecological surgery and musculoskeletal disorders such as muscular pain, pain associated with arthritis, and mild body ache, it said.
Commenting on the development, the company’s Managing Director Mahendra Patel said that globally, no liquid formulation of diclofenac for rectal administration is available. Lincoln Pharmaceuticals will be the first company to introduce this novel spray solution aimed at better patient compliance, rapid drug release & greater bioavailability.
The company said the diclofenac rectal suppository market is Rs 20 crore in India and growing at 16 percent per annum.
There is a huge export potential for this novel product and will start the product registration in Africa, Latin America, & Southeast Asia and gradually expand to other markets, Lincoln Pharma said.
Editor’s Note: Lincoln Pharma gets Indian patent, Lincoln Pharmaceuticals, diclofenac rectal spray, Indian patents, Drug Controller General of India (DCGI).